[gpt3]Summarize this content to 100 words:
April 12, 2025
1 min read
Key takeaways:
- From an enrollment of more than 5 million, crude prevalence of autosomal dominant polycystic kidney disease was 67.3 per 100,000 persons.
- Prevalence was lowest for Native American and Alaska Native populations.
BOSTON — Autosomal dominant polycystic kidney disease rates in the Military Health System are comparable to the general population, but with variability among certain groups, according to a speaker.
“It is an interesting study because the military health system is a universal health care system, so it looks at a group of patients who do not have the barriers to care that the general population in the United States does,” Rachael Silverberg, MD, of the Walter Reed National Military Medical Center in Bethesda, Maryland, told Healio.
Researchers used the Military Health System Data Repository, employing ICD-10 codes for autosomal dominant PKD diagnosis. The data were presented at the National Kidney Foundation Spring Clinical Meetings.
From an enrollment of 5,028,667 patients, 3,382 were diagnosed with autosomal dominant PKD, with a crude prevalence of 67.3 per 100,000 people. Patient eGFR was calculated from serum creatinine using the 2021 CKD-EPI equation. Median age was 47 years, 3.3% of patients were on dialysis and 8.5% had renal transplants.
Prevalence was highest in women, Black and non-Hispanic patients, according to Silverberg and colleagues. Meanwhile, Native American and Alaska Native populations had lower rates. When excluding patients on dialysis or those who underwent a transplant, 908 patients had available measurements of both eGFR and albuminuria, according to the study.
Of this group, 42% had an elevated risk for chronic kidney disease progression, indicated by an eGFR less than 60 mL/min/1.73 m² or albuminuria levels greater than 30 mg/g.
In autosomal dominant PKD, patients are often identified based on genetic testing, according to Silverberg. “Either they have a family member that tests positive, or they come to care, and they are identified with an abnormality … but there is a whole period of time when people are asymptomatic, so they are at risk for progression.”
In all, autosomal dominant PKD rates were similar to the general population, with some variability in sex, race and ethnicity. More than 40% of patients with autosomal dominant PKD are at increased risk for CKD progression. Further investigation is needed, Silverberg said.
The study “can [SC1] provide some information in terms of how we can identify these patients who are actually being treated,” Silverberg added. “It is the beginning of what I think could be the future.”
For more information:
Rachael Silverberg, MD, can be reached at rachael.silverberg@gmail.com.
Sources/Disclosures
Collapse
Silverberg R, et al. Abstract G-495. Presented at: NKF Spring Clinical Meetings; April 9-13, 2025; Boston.
Disclosures:
Silverberg reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.
[/gpt
Source link